secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2022-06-09T23:59:59+00:00
Accession:  0001628280-22-016698
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Biotherapeutics reports positive Phase 3 STRATUM results for roflumilast foam in seborrheic dermatitis
--------------------------------------------------------------------------------

- 80.1% of patients on roflumilast foam achieved IGA success at week 8 vs 59.2% vehicle (p<0.0001)
- 50.7% achieved an IGA score of clear at week 8 compared to 28.2% with vehicle (p<0.0001)
- Treatment was well-tolerated; discontinuation due to adverse events was 0.7% for roflumilast vs 2.0% for vehicle
- NDA submission to FDA for roflumilast foam in seborrheic dermatitis anticipated in first half of 2023

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000162828022016698/0001628280-22-016698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000162828022016698/arqt-20220606.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-016698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer